Trial Profile
Phase II Open Label Study to Evaluate the Biological Activity of ASLAN001 (ARRY 334543) in Patients With Recurrent/Metastatic Gastric, Gastro-oesophageal Junction, and Oesophageal Carcinoma Whose Tumours are Epidermal Growth Factor Receptor 2 (HER-2) Amplified or Co-Expressing Epidermal Growth Factor Receptor 1 (HER-1) and HER 2
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Apr 2023
Price :
$35
*
At a glance
- Drugs Varlitinib (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Sponsors ASLAN Pharmaceuticals; PharmaNet Development Group
- 08 Aug 2013 According to an Array BioPharma media release, positive results of this trial were reported in gastric cancer and a phase 2b study will be conducted.
- 07 Jun 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health, NCT01614522).
- 07 Jun 2012 Company (ASLAN Pharmaceuticals) and additional lead trial investigator (Lee KW) added as reported by ClinicalTrials.gov.